{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:39:41Z","timestamp":1791175181343,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.taap.2012.01.008","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T08:59:22Z","timestamp":1326877162000},"page":"263-268","source":"Crossref","is-referenced-by-count":74,"title":["Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins"],"prefix":"10.1016","volume":"259","author":[{"given":"P.","family":"Sirvent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bordenave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hillaire-Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Raynaud De Mauverger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lacampagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2012.01.008_bb0200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0002-9149(93)90438-I","article-title":"Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and\/or previous myocardial infarction","volume":"71","author":"Anon","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.taap.2012.01.008_bb0205","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Anon","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2012.01.008_bb0210","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","author":"Anon","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2012.01.008_bb0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrg2158","article-title":"Mutation rate variation in multicellular eukaryotes: causes and consequences","volume":"8","author":"Baer","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.taap.2012.01.008_bb0215","doi-asserted-by":"crossref","first-page":"III50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2012.01.008_bb0030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.bor.0000245730.25383.97","article-title":"Statin myopathy: an update","volume":"18","author":"Christopher-Stine","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.taap.2012.01.008_bb0220","doi-asserted-by":"crossref","first-page":"III39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2012.01.008_bb0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.taap.2012.01.008_bb0045","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-CoA reductase inhibitors","volume":"23","author":"Farmer","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2012.01.008_bb0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","article-title":"Regulation of the mevalonate pathway","volume":"343","author":"Goldstein","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.taap.2012.01.008_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.taap.2012.01.008_bb0225","doi-asserted-by":"crossref","first-page":"II42","DOI":"10.1161\/01.CIR.0000129500.29229.92","article-title":"Beyond the laboratory: clinical implications for statin pleiotropy","volume":"109","author":"Halcox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2012.01.008_bb0230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.freeradbiomed.2011.10.449","article-title":"Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes","volume":"52","author":"Kwak","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.taap.2012.01.008_bb0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1085\/jgp.111.2.207","article-title":"Modulation of the frequency of spontaneous sarcoplasmic reticulum Ca2+ release events (Ca2+ sparks) by myoplasmic [Mg2+] in frog skeletal muscle","volume":"111","author":"Lacampagne","year":"1998","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.taap.2012.01.008_bb0075","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.taap.2012.01.008_bb0080","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/jpet.106.118331","article-title":"Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum\/mitochondria Ca2+\u2212release system","volume":"321","author":"Liantonio","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2012.01.008_bb0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","article-title":"Isoprenoids as mediators of the biological effects of statins","volume":"110","author":"Liao","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2012.01.008_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11584380-000000000-00000","article-title":"Clinical implications of pharmacogenetic variation on the effects of statins","volume":"34","author":"Maggo","year":"2011","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2012.01.008_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/A:1006875517267","article-title":"Metabolic control analysis and threshold effect in oxidative phosphorylation: implications for mitochondrial pathologies","volume":"174","author":"Mazat","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.taap.2012.01.008_bb0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.taap.2007.06.003","article-title":"Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration","volume":"223","author":"Nadanaciva","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2012.01.008_bb0105","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2012.01.008_bb0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"Paiva","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2012.01.008_bb0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9149(00)00910-3","article-title":"Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering","volume":"86","author":"Pedersen","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.taap.2012.01.008_bb0120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","article-title":"Current overview of statin-induced myopathy","volume":"116","author":"Rosenson","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.taap.2012.01.008_bb0125","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/jpet.105.086462","article-title":"Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells","volume":"314","author":"Sacher","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2012.01.008_bb0130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2012.01.008_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1006834912257","article-title":"Permeabilized cell and skinned fiber techniques in studies of mitochondrial function in vivo","volume":"184","author":"Saks","year":"1998","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.taap.2012.01.008_bb0140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2012.01.008_bb0145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2012.01.008_bb0150","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbrc.2005.10.108","article-title":"Simvastatin induces impairment in skeletal muscle while heart is protected","volume":"338","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2012.01.008_bb0160","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.bbrc.2005.02.070","article-title":"Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle","volume":"329","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2012.01.008_bb0155","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.taap.2012.01.008_bb0165","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI13350","article-title":"Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy","volume":"108","author":"Takemoto","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2012.01.008_bb0170","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1152\/japplphysiol.00387.2004","article-title":"Relationships between maximal muscle oxidative capacity and blood lactate removal after supramaximal exercise and fatigue indexes in humans","volume":"97","author":"Thomas","year":"2004","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.taap.2012.01.008_bb0180","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.taap.2012.01.008_bb0175","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.taap.2012.01.008_bb0185","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1249\/00005768-199108000-00015","article-title":"A physical activity questionnaire for the elderly","volume":"23","author":"Voorrips","year":"1991","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.taap.2012.01.008_bb0190","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1096\/fj.02-1083fje","article-title":"Defects in ryanodine receptor calcium release in skeletal muscle from post-myocardial infarct rats","volume":"17","author":"Ward","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.taap.2012.01.008_bb0195","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.2337\/diabetes.54.11.3082","article-title":"Effects of diabetes on ryanodine receptor Ca release channel (RyR2) and Ca2+ homeostasis in rat heart","volume":"54","author":"Yaras","year":"2005","journal-title":"Diabetes"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X12000178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X12000178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T09:09:55Z","timestamp":1640509795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X12000178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0041008X12000178"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2012.01.008","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}